Gastrointestinal stromal tumors with a deficient SDH complex do not respond to imatinib treatment but, in line with the mechanism of oncogenesis, they respond to multitargeted TKIs, which are potent antiangiogenetic agents, such as sunitinib, regorafenib, and pazopanib [23,40,43,97,109,110,111,112]. Here, SDHB is linked to gastrointestinal stromal tumor.